Cargando…

Exploiting Oncogenic Drivers along the CCNG1 Pathway for Cancer Therapy and Gene Therapy

Detalles Bibliográficos
Autores principales:	Al-Shihabi, Ahmad, Chawla, Sant P., Hall, Frederick L., Gordon, Erlinda M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292824/ https://www.ncbi.nlm.nih.gov/pubmed/30581985 http://dx.doi.org/10.1016/j.omto.2018.11.002

Ejemplares similares

Cell cycle checkpoint control: The cyclin G1/Mdm2/p53 axis emerges as a strategic target for broad-spectrum cancer gene therapy - A review of molecular mechanisms for oncologists
por: Gordon, Erlinda M., et al.
Publicado: (2018)

MicroRNA-27a functions as an oncogene in human osteosarcoma by targeting CCNG1
por: Lin, Tao, et al.
Publicado: (2018)

Rexin-G(®), a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report
por: Kim, Seth, et al.
Publicado: (2017)

Insight into Oncogenic Viral Pathways as Drivers of Viral Cancers: Implication for Effective Therapy
por: Elkhalifa, Ahmed M. E., et al.
Publicado: (2023)

Exploiting signaling rewiring in cancer cells with co‐existing oncogenic drivers
por: Chiarle, Roberto, et al.
Publicado: (2023)

Advanced Phase I/II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Gemcitabine-resistant Metastatic Pancreatic Cancer
por: Chawla, Sant P, et al.
Publicado: (2009)

A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer
por: Chawla, Sant P., et al.
Publicado: (2018)

Phase I/II and Phase II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Chemotherapy-resistant Sarcoma and Osteosarcoma
por: Chawla, Sant P, et al.
Publicado: (2009)

Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long-term survival with DeltaRex-G: A case report and literature review
por: Morse, Michael A., et al.
Publicado: (2021)

Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives
por: Gordon, Erlinda M., et al.
Publicado: (2016)

Along signal paths: an empirical gene set approach exploiting pathway topology
por: Martini, Paolo, et al.
Publicado: (2013)

MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer
por: Hasegawa, S, et al.
Publicado: (2014)

CCNG2 Overexpression Mediated by AKT Inhibits Tumor Cell Proliferation in Human Astrocytoma Cells
por: Zhang, Danfeng, et al.
Publicado: (2018)

miR-1246 Targets CCNG2 to Enhance Cancer Stemness and Chemoresistance in Oral Carcinomas
por: Lin, Shih-Shen, et al.
Publicado: (2018)

miR-23b suppresses lung carcinoma cell proliferation through CCNG1
por: Han, Hongsheng, et al.
Publicado: (2018)

miR-23b suppresses lung carcinoma cell proliferation through CCNG1
por: Han, Hongsheng, et al.
Publicado: (2019)

Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver
por: Kim, So Yeon, et al.
Publicado: (2020)

Differential expression of cyclins CCNB1 and CCNG1 is involved in the chondrocyte damage of kashin-beck disease
por: Setiwalidi, Kaidiriye, et al.
Publicado: (2022)

Exploitation of the IDO Pathway in the Therapy of Rheumatoid Arthritis
por: Williams, Richard O.
Publicado: (2013)

lncRNA MSC-AS1 Aggravates Diabetic Nephropathy by Regulating the miR-325/CCNG1 Axis
por: Zhao, Hongtu, et al.
Publicado: (2022)

Exploiting NK Cell Surveillance Pathways for Cancer Therapy
por: Barrow, Alexander David, et al.
Publicado: (2019)

Retracted: lncRNA MSC-AS1 Aggravates Diabetic Nephropathy by Regulating the miR-325/CCNG1 Axis
por: Healthcare Engineering, Journal of
Publicado: (2023)

Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosis
por: Nicolai, S, et al.
Publicado: (2015)

Oncogenic drivers and mitochondrial dependency
por: Alvarez-Calderon, Francesca, et al.
Publicado: (2015)

Exploiting the Fanconi Anemia Pathway for Targeted Anti-Cancer Therapy
por: Jo, Ukhyun, et al.
Publicado: (2015)

Recent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung Cancer
por: Guo, Yijia, et al.
Publicado: (2019)

Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor–Based Cellular Therapy
por: Martinov, Tijana, et al.
Publicado: (2023)

MicroRNA-122-5p inhibits cell proliferation, migration and invasion by targeting CCNG1 in pancreatic ductal adenocarcinoma
por: Dai, Chen, et al.
Publicado: (2020)

SMYD3: An Oncogenic Driver Targeting Epigenetic Regulation and Signaling Pathways
por: Bottino, Cinzia, et al.
Publicado: (2020)

SWAN pathway-network identification of common aneuploidy-based oncogenic drivers
por: Bowers, Robert R, et al.
Publicado: (2022)

Exploiting Single-Cell Tools in Gene and Cell Therapy
por: Bode, Daniel, et al.
Publicado: (2021)

Mesothelioma Driver Genes, Ferroptosis, and Therapy
por: Felley-Bosco, Emanuela, et al.
Publicado: (2019)

Accurate Prediction of Cancer Prognosis by Exploiting Patient-Specific Cancer Driver Genes
por: Lee, Suyeon, et al.
Publicado: (2023)

Exploiting protease activation for therapy
por: Bleuez, Chloe, et al.
Publicado: (2022)

Oncogenic driver mutations in lung cancer
por: Luo, Susan Y, et al.
Publicado: (2013)

Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders
por: Naramura, Mayumi, et al.
Publicado: (2011)

Extracting Fitness Relationships and Oncogenic Patterns among Driver Genes in Cancer
por: Zhang, Xindong, et al.
Publicado: (2017)

Understanding oncogenicity of cancer driver genes and mutations in the cancer genomics era
por: Porta‐Pardo, Eduard, et al.
Publicado: (2020)

Oncogenic driver genes and tumor microenvironment determine the type of liver cancer
por: Wang, Gang, et al.
Publicado: (2020)

lncRNA LINC01494 Promotes Proliferation, Migration And Invasion In Glioma Through miR-122-5p/CCNG1 Axis
por: Li, Chang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_d1gmld7p5sln8oot7jdu45i6fm